Exalgo regulatory update

FDA approved an sNDA from Covidien's Mallinckrodt Inc. subsidiary for a 32 mg dose tablet of Exalgo hydromorphone to treat moderate to severe pain in opioid-tolerant patients. Zalicus said the 32 mg d...